Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Summary

Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in countries where ALK inhibitors are not approved or available. The protocol will further evaluate the safety of LDK378 in patients with ALK(+) NSCLC.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications